Dr Effects of Adiponectin, Plasma D-Dimer, Inflammation and Tumor Markers on Clinical Characteristics and Prognosis of Patients with Ovarian Cancer

Adiponectin, Plasma D-Dimer, Inflammation and Tumor Markers on Clinical Characteristics and Prognosis of Patients with Ovarian Cancer

  • Hui Li The Fourth Hospital of Shijiazhuang(Obstetrics and Gynaecology Hospital)
Keywords: adiponectin, plasma D-dimer, inflammatory factors, tumor markers, ovarian cancer

Abstract


 [Abstract] Objective: To investigate the effects of adiponectin (ADPN), plasma D-dimer (D-D), inflammation and tumor markers on clinical characteristics and prognosis of patients with ovarian cancer. Methods: A total of 80 patients with ovarian cancer treated in our hospital from April 2017 to November 2019 were enrolled as study subjects and evenly divided into observation group (patients with ovarian cancer) and control group (patients with benign ovarian tumor) based on the results of postoperative pathological biopsy. The levels of ADPN, plasma D-D, inflammatory factors and serum tumor markers [carbohydrate antigen 125 (CA125), human epididymis protein 4 (HE4) and risk of ovarian malignancy algorithm (ROMA)] were compared between the two groups. The diagnostic value of serum tumor markers CA125, HE4 and ROMA in ovarian cancer was explored. The correlations of the changes of ROMA with the changes in the levels of ADPN, plasma D-D, high-sensitivity C-reactive protein (hs-CRP), CA125 and HE4 were analyzed. Additionally, the related risk factors affecting the development of ovarian cancer were subjected to univariate and multivariate logistic regression analyses. Results: In comparison with control group, observation group exhibited a lowered ADPN level (p<0.05), notably raised levels of plasma D-D, inflammatory factors hs-CRP and interleukin-6 (IL-6) and serum tumor markers CA125 and HE4 and an evidently increased ROMA (p<0.05). Besides, the detection of serum ROMA showed the highest specificity and sensitivity and low false positive rate and false negative rate. The changes of ROMA were positively correlated with the changes in the levels of plasma D-D, hs-CRP, CA125 and HE4 (p<0.05), and negatively associated with the changes in ADPN level (p<0.05). The results of univariate analysis showed that abnormal ADPN, D-D, hs-CRP, IL-6, CA125 and HE4 levels were related risk factors affecting the development of ovarian cancer. It was found through multivariate logistic regression analysis that decreased ADPN level and increased D-D, hs-CRP, IL-6, CA125 and HE4 levels were independent risk factors affecting the development of ovarian cancer. Conclusion: In the case of ovarian cancer, the ADPN level declines, while the levels of plasma D-D, inflammatory factors, and serum tumor markers CA125, HE4 and ROMA rise obviously. Besides, the ROMA level displays a positive relation to the content of CA125, HE4, plasma D-D and inflammatory factors and a negative association with ADPN level.

References

[1]Albers CE, Ranjit E, Sapra A, Bhandari P, Wasey W.Clinician Beware, Giant Ovarian Cysts are Elusive and Rare.Cureus,2020,12(1):e6753.
[2]Choi J, Park CS, Seong MK, Seol H, Kim JS, Park IC, Noh WC, Kim HA.Predicting the Benefit of Adjuvant Aromatase Inhibitor Therapy in Postmenopausal Breast Cancer Patients with Phosphorylated S6K1 Expression Status.J Breast Cancer,2019,23(1):10-19. 
[3]Ostmeyer J, Lucas E, Christley S, Lea J, Monson N, Tiro J, Cowell LG.Biophysicochemical motifs in T cell receptor sequences as a potential biomarker for high-grade serous ovarian carcinoma.PLoS One,2020,15(3):e0229569.
[4]Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.Mol Cancer,2020,19(1):49. 
[5]Kaur K, Rajeshwari M, Gurung N, Kumar H, Sharma MC, Yadav R, Kumar S, Manchanda S, Singhal S, Mathur SR.Uterine tumor resembling ovarian sex cord tumor: A series of six cases displaying varied histopathological patterns and clinical profiles.Indian J Pathol Microbiol,2020,63(Supplement):S81-S86. 
[6]Chen Z, Guo X, Sun S, Lu C, Wang L.Serum miR-125b levels associated with epithelial ovarian cancer (EOC) development and treatment responses.Bioengineered,2020,11(1):311-317. 
[7]Hurley LC, Levin NK, Chatterjee M, Coles J, Muszkat S, Howarth Z, Dyson G, Tainsky MA.Evaluation of paraneoplastic antigens reveals TRIM21 autoantibodies as biomarker for early detection of ovarian cancer in combination with autoantibodies to NY-ESO-1 and TP53.Cancer Biomark,2020,27(3):407-421. 
[8]Miao R, Badger TC, Groesch K, Diaz-Sylvester PL, Wilson T, Ghareeb A, Martin JA, Cregger M, Welge M, Bushell C.Assessment of peritoneal microbial features and tumor marker levels as potential diagnostic tools for ovarian cancer.PLoS One,2020,15(1):e0227707. 
[9]Singh MS, Goldsmith M, Thakur K, Chatterjee S, Landesman-Milo D, Levy T, Kunz-Schughart LA, Barenholz Y.An ovarian spheroid based tumor model that represents vascularized tumors and enables the investigation of nanomedicine therapeutics.Nanoscale,2020,12(3):1894-1903. 
[10]Nomelini RS, Carrijo Chiovato AF, Abdulmassih FBF, da Silva RC, Tavares-Murta BM, Murta EFC.Neutrophil-to-lymphocyte ratio and platelet count as prognostic factors in ovarian malignancies.J Cancer Res Ther,2019,15(6):1226-1230. 
[11]Salminen L, Nadeem N, Jain S, Grènman S, Carpén O, Hietanen S, Oksa S, Lamminmäki U, Pettersson K, Gidwani K.A longitudinal analysis of CA125 glycoforms in the monitoring and follow up of high grade serous ovarian cancer.Gynecol Oncol,2020,156(3):689-694.
[12]Iwahashi N, Inai Y, Minakata S, Sakurai S, Manabe S, Ito Y, Ino K, Ihara Y.C-Mannosyl tryptophan increases in the plasma of patients with ovarian cancer.Oncol Lett,2020,19(1):908-916.
[13]Maděrka M, Pilka R, Neubert D, Hambálek J.New serum tumor markers S100, TFF3 and AIF-1 and their possible use in oncogynecology.Ceska Gynekol,2019,84(4):303-308. 
[14]Turashvili G, Fix DJ, Soslow RA, Park KJ.Wilms Tumor of the Ovary: Review of the Literature and Report of 2 Cases.Int J Gynecol Pathol,2020,39(1):72-78. 
[15]Chin CD, Fares CM, Konecny GE, Rao J.Biomarkers that may predict response to immunotherapy in ovarian malignancies.Curr Opin Obstet Gynecol,2020,32(1):84-90.
[16]Wolf D, Fiegl H, Zeimet AG, Wieser V, Marth C, Sprung S, Sopper S, Hartmann G, Reimer D, Boesch M.High RIG-I expression in ovarian cancer associates with an immune-escape signature and poor clinical outcome.Int J Cancer,2020,146(7):2007-2018. 
[17]Sullivan MW, Modesitt SC.When to Worry about Cancer: Concurrent Carcinoma and Recurrence in Borderline Ovarian Tumors.South Med J,2019,112(12):634-638. 
[18]Li H, Terry MB, Antoniou AC, Phillips KA, Kast K, Mooij TM, Engel C, Noguès C, Stoppa-Lyonnet D, Lasset C.Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for BRCA1 and BRCA2 Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium.Cancer Epidemiol Biomarkers Prev,2020,29(2):368-378.
[19]Ascierto PA, Bifulco C, Buonaguro L, Emens LA, Ferris RL, Fox BA, Delgoffe GM, Galon J, Gridelli C, Merlano M.Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge 2018" (28-29 November, 2018, Naples, Italy).J Immunother Cancer,2019,7(1):332-336.
[20]Zong L, Zhou Y, Zhang M, Chen J, Xiang Y. VISTA expression is associated with a favorable prognosis in patients with high-grade serous ovarian cancer.Cancer Immunol Immunother,2020,69(1):33-42. 
Published
2021/08/18
Section
Original paper